Boston Scientific Corporation reported favorable six-month results from the first 60 patients enrolled in the REPRISE II clinical trial evaluating the safety and performance of the LotusTM Valve System in symptomatic patients with severe aortic stenosis considered at high risk for surgical valve replacement. The data, which were presented at PCR London Valves and formally received the honor of Best Abstract 2013, demonstrated excellent results with no new valve-related adverse events between 30 days and six months...
More...
More...